As result of the great benefit of HAART, AIDS-related deaths have dramatically declined
during the last decade in HIV-infected individuals. However, mortality due to non-AIDS …

AIDS: Reports of metabolic disorders, such as diabetes mellitus and hyperlipidemia,
occurring during treatment with protease inhibitor (PI) regimens are prompting patients and …

Highly active antiretroviral therapy (HAART) regimens, especially those including protease
inhibitors have been shown to cause, in a high proportion of HIV-infected patients, a …

Cardiovascular complications in the course of human immunodeficiency virus (HIV) infection
are multifactorial and may be caused by the virus itself or by the related opportunistic …

Highly active antiretroviral therapy (HAART) has significantly improved the prognosis for
many individuals with HIV infection. Consequently, HIV infection has become a chronic and …

Background Metabolic diseases are frequently observed in HIV‐infected persons and, as
the risk of contracting these diseases is age‐related, their prevalence will increase in the …

Objective: Alterations in glucose and lipid metabolism, lactic acidemia, bone disorders, and
abnormal body fat distribution have been recognized recently as frequent complications …

Use of highly active antiretroviral therapy (HAART) is associated with the development of
traditional cardiovascular risk factors, including dyslipidemia and insulin resistance. Recent …

Highly active antiretroviral therapy (HAART) commonly leads to persistent dyslipidemia and
insulin resistance that appear likely to confer an increased incidence of cardiovascular …

The development of new drugs against HIV infection has evolved at a rapid pace. The first
agent for the treatment of HIV, zidovudine, was approved in 1987 and in the following 11 …